Cargando…

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

BACKGROUND: The gefitinib compassionate-use programme has enabled >39,000 patients worldwide to receive gefitinib ('Iressa', ZD1839) treatment. This paper reports the outcome of gefitinib treatment in Chinese patients who enrolled into the 'Iressa' Expanded Access Programme (E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mu, Xin-Lin, Li, Long-Yun, Zhang, Xiao-Tong, Wang, Shu-Lan, Wang, Meng-Zhao
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC516034/ https://www.ncbi.nlm.nih.gov/pubmed/15318946 http://dx.doi.org/10.1186/1471-2407-4-51

Ejemplares similares

Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
por: Blackledge, G, et al.
Publicado: (2004)

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer
por: Kirby, A M, et al.
Publicado: (2006)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
por: Sewell, J M, et al.
Publicado: (2002)

Molecular mechanisms underlying the interaction between ZD1839 (‘Iressa’) and cisplatin/5-fluorouracil
por: Magné, N, et al.
Publicado: (2003)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Sequence-dependent effects of ZD1839 (‘Iressa’) in combination with cytotoxic treatment in human head and neck cancer
por: Magné, N, et al.
Publicado: (2002)

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
por: Parra, H S, et al.
Publicado: (2004)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model
por: Williams, K J, et al.
Publicado: (2002)

Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
por: Maddineni, S B, et al.
Publicado: (2005)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
por: Giannelli, G, et al.
Publicado: (2004)

Lessons from the ‘Iressa’ Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations
por: Stahel, R, et al.
Publicado: (2003)

The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours
por: Knight, Louise A, et al.
Publicado: (2004)

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases
por: Cappuzzo, F, et al.
Publicado: (2003)

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006)

Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA)
por: Kimura, H, et al.
Publicado: (2007)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)
por: Kokubo, Y, et al.
Publicado: (2005)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
por: Camirand, Anne, et al.
Publicado: (2005)

On the causes of fevers (1839)
por: Pelling, Margaret
Publicado: (1986)

Escritos jurídicos (1839-1863) : antología
por: Rodríguez de San Miguel, Juan N.
Publicado: (1992)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

Compassionate use programmes for rare diseases: proposals for actions
por: Houÿez, François, et al.
Publicado: (2012)

Memorias inéditas, 1839, 1840, 1841
Publicado: (1973)

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
por: Monks, N R, et al.
Publicado: (2001)

Literatura alicantina, 1839-1939 : ensayo crítico y bio-bibliográfico.
por: Ramos, Vicente 1919-
Publicado: (1966)

Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status
por: Wei, Zhong, et al.
Publicado: (2008)

Correspondencia diplomática franco-mexicana, 1808-1839
Publicado: (1957)

Transactions of the Scandinavian Society of Naturalists and Physicians, 1839
Publicado: (1840)

Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma
por: Gemmill, R M, et al.
Publicado: (2005)

The Higgs as a portal to the hidden sector via an analysis of $H\to Zd_d Z_d \to 4l$ using the ATLAS detector
por: Unwuchola, D A
Publicado: (2015)

Paul Cézanne 1839-1906 : la naturaleza se convierte en arte /
por: Düchting, Hajo
Publicado: (1994)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Intervención francesa, 1838-1839 : la diplomacia mexicana y el imperialismo del librecambio /
por: Aquino Sánchez, Faustino A.
Publicado: (1997)

Compassionate Treatment of Brainstem Tumors with Boron Neutron Capture Therapy: A Case Series
por: Chen, Yi-Wei, et al.
Publicado: (2022)

La prensa infantil de México (1839-1984)
por: Lombardo García, Irma
Publicado: (1984)

Cannot write session to /tmp/vufind_sessions/sess_06m9r0pji234fm98cdsecuje9g